Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis - Dorlo, T. P. C.; Balasegaram, M.; Beijnen, J. H.; de Vries, P. J. (Journal of antimicrobial chemotherapy, 2012)
Keywords: Antibiotics; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiprotozoal Agents - adverse effects; Antiprotozoal Agents - pharmacokinetics; Antiprotozoal Agents - pharmacology; Antiprotozoal Agents - therapeutic use; Biological and medical sciences; Cancer; Cells; Clinical trials; Clinical Trials as Topic; Human protozoal diseases; Humans; Infectious diseases; Leishmania; Leishmania - drug effects; Leishmaniasis - drug therapy; Leshmaniasis; Medical sciences; Parasites; Parasitic diseases; Pharmacology. Drug treatments; Phosphorylcholine - adverse effects; Phosphorylcholine - analogs & derivatives; Phosphorylcholine - pharmacokinetics; Phosphorylcholine - pharmacology; Phosphorylcholine - therapeutic use; Protozoal diseases; Side effects; Treatment Outcome; East Africa; South Asia; Asia; Africa; India; Antineoplastic agent; Skin disease; Protozoal disease; antiprotozoal agents; Phospholipid; Kala azar; Review; Cutaneous leishmaniasis; Antiprotozoal agent; alkylphosphocholine; Mechanism of action; Kinetoplastida; Protozoa; Pharmacodynamics; antiparasitic agents; Treatment efficiency; Leishmaniasis; Parasitosis; Biological activity; Infection; Miltefosine; Treatment; Leishmania; Lysophospholipid; Clinical pharmacology; Parasiticide; pre-clinical pharmacology; Pharmacokinetics; visceral leishmaniasis; Bibliographic review